The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients
Open accessAbstract
The concept of adaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and name of AL should be broadened. Against this background of ongoing debate, we examine the environmental changes that will likely make adaptive pathways the preferred approach in the future. The key drivers include: growing patient demand for timely access to promising therapies, emerging science leading to fragmentation of treatment populations, rising payer influence on product accessibility, and pressure on pharma/investors to ensure sustainability of drug development. We also discuss a number of environmental changes that will enable an adaptive paradigm. A life‐span approach to bringing innovation to patients is expected to help address the perceived access vs. evidence trade‐off, help de‐risk drug development, and lead to better outcomes for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789
Cited by
Kalra, N., & Paddock, S. M. (2016) · Transportation Research Part A: Policy and Practice · doi:10.1016/j.tra.2016.09.010 · Cited by 1,221
Berger, M. L., Sox, H., Willke, R. J., Brixner, D. L., Eichler, H., Goettsch, W., Madigan, D., Makady, A., Schneeweiss, S., Tarricone, R., et al. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4297 · Cited by 344
Self-citationWhen and how can real world data analyses substitute for randomized controlled trials?
Franklin, J. M., & Schneeweiss, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.857 · Cited by 316
The future of rodent models in depression research
Gururajan, A., Reif, A., Cryan, J. F., & Slattery, D. A. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0221-6 · Cited by 269
Wallis, R. S., Maeurer, M., Mwaba, P., Chakaya, J., Rustomjee, R., Migliori, G. B., Marais, B., Schito, M., Churchyard, G., Swaminathan, S., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00070-0 · Cited by 262
Grskovic, M., Hiller, D. J., Eubank, L. A., Sninsky, J. J., Christopherson, C., Collins, J. P., Thompson, K., Song, M., Wang, Y. S., Ross, D., et al. (2016) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.07.003 · Cited by 258
Gray, C. M., Grimson, F., Layton, D., Pocock, S., & Kim, J. (2020) · Drug Safety · doi:10.1007/s40264-020-00944-1 · Cited by 65
Niazi, S. K. (2025) · Pharmaceuticals · doi:10.3390/ph18091271 · Cited by 61
Innovating global regulatory frameworks for generative AI in medical devices is an urgent priority
Ong, J. C. L., Ning, Y., Liu, M., Ma, Y., Zhao, L., Singh, K., Chang, R. T., Vogel, S., Lim, J. C. W., Tan, I. S. K., et al. (2026) · npj Digital Medicine · doi:10.1038/s41746-026-02552-2 · Cited by 7
Metadata
- Authors
- Eichler, H., Baird, L., Barker, R., Bloechl‐Daum, B., Børlum‐Kristensen, F., Brown, J., Chua, R., Del Signore, S., Dugan, U., Ferguson, J., Garner, S., Goettsch, W., Haigh, J., Honig, P., Hoos, A., Huckle, P., Kondo, T., Le Cam, Y., Leufkens, H., Lim, R., Longson, C., Lumpkin, M., Maraganore, J., O'Rourke, B., Oye, K., Pezalla, E., Pignatti, F., Raine, J., Rasi, G., Salmonson, T., Samaha, D., Schneeweiss, S., Siviero, P., Skinner, M., Teagarden, Jr., Tominaga, T., Trusheim, M., Tunis, S., Unger, T., Vamvakas, S., & Hirsch, G.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2015-02-04
- Volume
- 97
- Issue
- 3
- Pages
- 234-246
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1965717563
- Cited by
- 196
- References
- 1
- FWCI
- 84.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.